Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027
Abbott announced plans to separate its Nutrition business into a standalone publicly traded company by the end of 2027, creating...
Abbott’s Scorecard: What the Call Promised, What the Filings Show, and Where the Gap Lives
On the morning of October 21, 2026, Abbott's chief executive stepped onto a call with analysts and described a company...
Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway
Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady...
GE Aerospace raises 2026 guidance as commercial services orders surge 58 percent
GE Aerospace lifted full-year profit and cash flow targets after third-quarter orders jumped 58 percent, driven by a backlog of...
Evidence Sheet: Honeywell International (HON)
The standing BullScope yardsticks for Honeywell International, computed from official filings and refreshed with each new edition.
One Drug, Nearly a Billion Dollars, and a Pipeline That Just Blinked
The short version Krystal Biotech built a profitable, cash-rich business on a single gene therapy approved just three years ago....
Vertex Pharmaceuticals: Three Things the Street Is Saying, and What the Filings Actually Show
Vertex spent most of the last decade as a one-disease company that happened to be extraordinarily good at that disease....
Evidence Sheet: Chevron (CVX)
The standing BullScope yardsticks for Chevron, computed from official filings and refreshed with each new edition.
Ardelyx: The Revenue Is Real, the Guidance Cut Is Realer
Three years ago, Ardelyx was burning through cash with almost nothing to show at the pharmacy counter. Then IBSRELA, its...
Innoviva: The Royalties Are Shrinking. The Specialty Business Is Growing. Both Things Are True at Once.
Innoviva spent most of its life as a toll booth on two GSK inhalers. Every time a patient filled a...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.